Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Community acquired pneumonia (CAP) is one of the most common and morbid conditions encountered in clinical practice, which causes serious morbidity worldwide. In CAP, oxidative stress is linked to inflammation, demonstrated by increased production of interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which attract inflammatory cells and increase oxidant production by these cells. Attenuation of oxidative stress via antioxidants would be expected to result in reduced pulmonary damage. Antioxidants have been found to be effective in alleviating lung injury and protecting against damage of other organs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Astaxanthin Supplementation

NCT06511960

Dietary Supplements

COMPLETED NA

Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers

NCT01056094

Oxidative Stress in Healthy Subjects

UNKNOWN PHASE1/PHASE2

A Study to Evaluate the Effect of Astaxanthin in Healthy Participants

NCT05376501

Healthy

COMPLETED NA

Evaluation of Astaxanthin Properties on Anti-fatigue

NCT06593535

Healthy Volunteer

COMPLETED NA

Astaxanthin Supplementation in Cyclists

NCT01241877

Athletic Performance

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be randomized controlled trial, that will be carried out at ICU at El Matarya Teaching Hospital.

Prior to participation in the study, written informed consent will be obtained from the patients or their family.

Patients with the following criteria will be enrolled: age ≥ 18 year, having clinical symptoms suggestive of CAP such as cough (with or without sputum), fever (\> 38.5°C), pleuritic chest pain or dyspnea and consolidations on computed Tomography (CT). Patients will be excluded from the study if having one of the following criteria: advanced age (≥70 years old), presence of severe immunosuppression (HIV infection, use of immune suppressants), malignancy, other concurrent infections, obstruction pneumonia (e.g., because of lung cancer), pneumonia developed within two weeks after hospital discharge, use of ASX before study entry, hypersensitivity to ASX, taking warfarin, taking other antioxidants such as vitamin C, vitamin E, glutathione, granulocytopenia (\<1000 neutrophils/mm3), renal failure, liver failure, pregnant and lactating women, hemodynamically unstable patients.

Eligible CAP patients at El Matarya Teaching Hospital will be randomly assigned to either ASX group or control group. The ASX group will receive ASX (12mg/d) orally or enterally in addition to conventional therapy for CAP. \[1,2\] The control group will receive placebo orally or enterally in addition to conventional therapy for CAP. \[2\] The treatment duration will be from hospital admission till time of discharge for each CAP patient.

All patients will be subjected to the following:

A. Patient Data Collection:

1. Baseline characteristics: demographic data of the participants including: age, gender, weight, height, and body mass index (BMI).
2. Medication History: complete history of medication will be recorded for each patient including medications for comorbidities and past medication history as well as concomitant medications.
3. Medical History: patient history will be recorded including history of present illness as well as comorbidities.

B. Clinical Assessment:

1. Physical Examination: daily records of ABGS, body temperature, pulse, blood pressure, and respiratory rate will be collected, baseline and final readings will be used for analysis.
2. Biochemical Investigations:

2.1 The biochemical parameters include complete blood count with differential counts of total leukocyte count, lymphocytic count, liver function, renal functions, albumin level, creatinine level, alkaline phosphatase level, ferritin level, C-reactive protein, Prothrombin time (PT), activated partial thromboplastin time APTT, lipid profile and blood sugar level , baseline and final readings will be used for analysis.

2.2 Cytokine storm parameters (interleukin-6, tumor necrosis factor-α, and interleukin10) will be assessed at baseline and at the end of the study.

C. Severity Assessment: CURB-65 severity score that has been validated for predicting mortality of CAP, will be assessed at baseline and at the end of the study.\[3\] D. Radiological Assessment of CAP: computed tomography will be carried out before enrollment to confirm pneumonia diagnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention

Group Type ACTIVE_COMPARATOR

Astaxanthin Oral Capsule

Intervention Type DRUG

12 mg of astaxanthin oral capsule

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

starch placebo capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Astaxanthin Oral Capsule

12 mg of astaxanthin oral capsule

Intervention Type DRUG

Placebo

starch placebo capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 year
* Clinical: Having symptoms suggestive of CAP such as cough (with or without sputum), fever (\> 38.5°C), pleuritic chest pain or dyspnea.
* Radiologic: consolidations on computed Tomography (CT).

Exclusion Criteria

* Advanced age (≥70 years old). Presence of severe immunosuppression (HIV infection, use of immune suppressants).

Malignancy. Other concurrent infections, obstruction pneumonia (e.g., because of lung cancer).

Pneumonia developed within two weeks after hospital discharge. Use of ASX before study entry. Hypersensitivity to ASX. Taking warfarin.

* Taking other antioxidants such as vitamin C, vitamin E, glutathione.
* Granulocytopenia (\<1000 neutrophils/mm3).
* Renal failure.
* Liver failure.
* Pregnant and lactating women.
* Hemodynamically unstable patients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No